Modality
Gene Editing
MOA
CAR-T BCMA
Target
WEE1
Pathway
Innate Imm
UCAMLBreast Ca
Development Pipeline
Preclinical
~May 2017
→ ~Aug 2018
Phase 1
Nov 2018
Phase 1Current
NCT08644748
1,635 pts·Breast Ca
2018-11→TBD·Not yet recruiting
1,635 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-03-011mo agoConference· Breast Ca
Trial Timeline
Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2
P1
Not yet…
Catalysts
Conference
2026-03-01 · 1mo ago
Breast Ca
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08644748 | Phase 1 | Breast Ca | Not yet recr... | 1635 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| TAK-2403 | Takeda | Phase 2 | WEE1 | |
| Fixazanubrutinib | Amgen | Phase 2 | PI3Kα | |
| Sovacapivasertib | Amgen | Phase 3 | WEE1 | |
| REG-8074 | Regeneron | Phase 2/3 | KRASG12C | |
| Fixaglumide | Genmab | Phase 2/3 | WEE1 | |
| Sovarasimod | Halozyme | Phase 1/2 | WEE1 | |
| JAZ-8729 | Jazz Pharma | Phase 2/3 | FcRn | |
| ACA-2691 | Acadia Pharma | Phase 3 | BCMA |